Cardiomiopatia dilatada – nova abordagem terapêutica
Palavras-chave:
Cardiomiopatia dilatada, imunoadsorção, auto-anticorpos cardíacosResumo
A cardiomiopatia dilatada ocorre na presença de uma reacção
inflamatória. Neste contexto, nas últimas duas décadas tem sido
estudada a existência de auto-anticorpos cardíacos assim como
o processo de infiltração cardíaca por células inflamatórias. Hoje
em dia percebem-se melhor os mecanismos patogénicos subjacentes ao processo. Recentemente, o esforço de investigação
nesta área centrou-se numa abordagem terapêutica em função da
etiologia. O processo de remoção de auto-anticorpos circulantes
pelo método da imunoadsorção tem demonstrado bons resultados
clínicos, ecocardiográficos, hemodinâmicos e laboratoriais na
cardiomiopatia dilatada. Neste artigo pretendeu-se rever o tema
abordando a literatura recente sobre classificação da doença,
mecanismos fisiopatológicos e terapêutica.
Downloads
Referências
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93:841-842.
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Duborg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. EurHeart J 2008;29:270-276.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies, an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups, and council on epidemiology and prevention. Circulation 2006;113:1807-1816.
Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18:619-624.
Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus, a status report. Herz 2000; 25:200–209.
Haake H. [Immunoglobulintherapy in inflammatory myocardial diseases]. Universitätsklinikum Gießen und Marburg, Marburg; 2008. German
Dörffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G, Reinke P. Short term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1995;1994-1997.
Caforio AP, Grazzini M, Mann J, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S. Identification of α- and β-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992; 85:1734-1742.
Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000; 101:385-391.
Iwata M, Yoshikawa T, Baba A et al. Autoimmunity against the second extracellular loop of beta-1 adrenergic receptor inducesβadrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 2001; 88:578-586.
Maisch B, Bauer E, Cirsi M et al. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation 1993; 87(5):V49–56.
Pankuweit S, Baandrup U, Moll R et al. Prevalence of parvovirus B 19 genome in endomyocardial biopsy specimen. Hum Pathol 2003; 34:80-86.
Kuhl U, Pauschinger M, Seeberg B et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965-1970.
Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879-886.
Tiburcy M. [Dilated Cardiomyopathy]. Greifswald Universität, 2007. German.
Hui-Rong L, Rong-Rui Z, Xiang-Ying J, Ying-Yuan W, Fu M. Relationship of Myocardial Remodeling to the Genesis of Serum Autoantibodies to Cardiac Beta1-Adrenoceptors and Muscarinic Type 2 Acetylcholine Receptors in Rats. J Am Coll Cardiol 2002; 39:1866-1873.
Caforio AP, Keeling PJ, Zachara E et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 1994; 344:773–777.
Zhang WG, Ma AQ, Wei J et al. Study of autoantibodies against the adenine nucleotide translocator in idiopathic dilated cardiomyopathy. Blood Press 1996; (3):45-48.
Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T, Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological changes in immunized rabbits. J Mol Cell Cardiol 2007; 29;641-655.
Goin JC, Borda ES, Auger S et al. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. Heart 1999; 82:273–278.
Wallukat G, Wollenberger A, Morwinski R et al. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Am Coll Cardiol 1995; 27:397-406.
Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernecke KD, Baumann G, Stangl K. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39:646-652.
Staudt A, Staudt Y, Dörr M, Böhm M, Knebel F, Hummel A, Wunderle L, Tiburcy M, Wernecke K, Baumann G, Felix S. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:829-836.
Staudt A, Dörr M, Staudt Y, et al. Role of immunoglobulin G-3 subclass in dilated cardiomyopathy—results from protein-A immunoadsorption. Am Heart J 2005; 150:729-736.
Staudt A, Staudt, Y, Hummel A, Empen K, Dörr M, Trimpert C, Birkenmeier K, Kühl U, Noutsias M, Russ D, Felix S. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Therapeutic Apheresis and Dialysis 2006; 10(1):42-48.
Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction
among patients suffering from dilated cardiomyopathy. Circulation. 2002; 106:2448-2453.
Mobini R, Staudt A, Felix SB et al. Hemodynamic improvement and removal of autoantibodies against b1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 423:115-119.
Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix S. Immunoadsorption in dilated cardiomyopathy: 6 month results from a randomized study. Am Heart J 2006; 152:712.e1-712.
Knebel F, Bohm M, Staudt A et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol 2004; 97:517-520.
Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35:1590-1598.
Elliot, P. Diagnosis and management of dilated cardiomyopathy. Heart 2000; 84:106-112.
Hunt SA et al. ACC/AHA Guideline Update 2005 for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005;112;e154-e235.
Sirajuddin, SA, AB, Miller, AB, Geraci, SA. Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: a critical literature review. J Card Fail 2002:48-53.
Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland S, Aukrust P. Immunomodulating Therapy with Intravenous Immunoglobulin in Patients with Chronic Heart Failure. Circulation 2001;103;220-225.
McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95:2476-2478
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
